Inspra (Eplerenone)

Eplerenone selectively binds to mineralocorticoid receptors in the distal nephron, preventing aldosterone from stimulating sodium reabsorption and potassium excretion. This antagonism promotes natriuresis while retaining potassium, leading to reduced blood volume and pressure. In cardiac tissue, the blockade diminishes aldosterone‑driven fibrosis and remodeling, supporting improved ventricular function.

The dosage of Inspra is individualized by a qualified healthcare professional based on the patient’s clinical condition, renal function, and potassium levels. The prescriber determines the appropriate starting dose and any subsequent adjustments, ensuring safe and effective therapy while monitoring laboratory parameters.

Safety data for eplerenone in pregnancy are limited, and the drug should be used only if the potential benefit justifies the potential risk to the fetus. It is excreted in breast milk, so caution is advised for nursing mothers, and a healthcare provider should evaluate the risk‑benefit profile before continuation.

To request Inspra, visit the product page on gnhindia.com, enter the desired quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any required import documentation.

Both eplerenone and spironolactone are aldosterone antagonists, but eplerenone is more selective for the mineralocorticoid receptor, resulting in fewer anti‑androgenic side effects such as gynecomastia. Spironolactone may have a broader hormonal profile, while eplerenone often offers a better tolerability profile for patients sensitive to hormonal side effects.

Inspra should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original packaging to protect them from moisture and light, and ensure the container is tightly closed when not in use.

Inspra is taken orally, usually once daily, with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed.

The most serious risks include severe hyperkalemia, which can cause cardiac arrhythmias, and acute kidney injury, which may lead to rapid loss of renal function. Patients should have regular monitoring of serum potassium and renal parameters, and the drug should be discontinued if dangerous elevations occur.

Inspra is contraindicated in individuals with known hypersensitivity to eplerenone, those with severe hyperkalemia (serum potassium >5.0 mmol/L), and patients with significant renal impairment where potassium clearance is compromised. It should also be avoided in patients taking other potassium‑sparing agents without careful monitoring.